Seres Therapeutics, Inc.

Equities

MCRB

US81750R1023

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:51:53 2024-05-16 pm EDT			5-day change	1st Jan Change
0.933 ^USD	-2.60%		-10.05%	-33.82%

May. 09	Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating	MT
May. 09	Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating	MT

Seres Therapeutics, Inc. Announces Resignation of Michele Trucksis as Executive Vice President and Chief Medical Officer

November 21, 2018 at 08:50 am EST

Michele Trucksis, Ph.D., M.D. notified Seres Therapeutics, Inc. of her resignation as the Executive Vice President and Chief Medical Officer of the Company. In connection with Dr. Trucksis' resignation, on November 16, 2018, the Company entered into a separation agreement (the Separation Agreement) and a consulting agreement (the Consulting Agreement) with Dr. Trucksis.

Latest news about Seres Therapeutics, Inc.

Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating	May. 09	MT
Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating	May. 09	MT
Transcript : Seres Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Seres Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Foreign automakers eager for Chinese partners at Beijing auto show	Apr. 26	RE
Battle for 'tech luxury' in China as EVs get smarter - and cheaper	Apr. 25	RE
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT	Apr. 09	CI
Declaration of Voting Results by Seres Therapeutics	Apr. 08	CI
Oppenheimer Adjusts Seres Therapeutics Price Target to $5 From $9, Maintains Outperform Rating	Mar. 06	MT
Chardan Cuts Price Target on Seres Therapeutics to $8 From $10 on Higher Expected Sharecount Dilution, Keeps Buy Rating	Mar. 06	MT
Seres Therapeutics Files a Definitive Proxy Statement with Securities and Exchange Commission	Mar. 05	CI
Seres Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Transcript : Seres Therapeutics, Inc., Q4 2023 Earnings Call, Mar 05, 2024	Mar. 05
North American Morning Briefing : S&P 500 Futures -2-	Mar. 05	DJ
Seres Therapeutics, Inc. Announces Chief Financial Officer Changes	Feb. 26	CI
Seres Therapeutics Appoints Marella Thorell as Executive Vice President	Feb. 26	CI
Kenneth Steiner Submits a Shareholder Proposal to Seres Therapeutics	Feb. 23	CI
Oppenheimer Trims Seres Therapeutics Price Target to $9 From $10, Maintains Outperform Rating	Jan. 16	MT
Transcript : Seres Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:45 AM	Jan. 10
Seres Therapeutics Shares Rise 15% After Getting FDA Fast-Track Designation for Infection Treatment	Jan. 09	DJ
Seres Therapeutics Announces VOWST? Commercial Launch Update and US FDA Fast Track Designation for SER-155	Jan. 09	CI
Seres Therapeutics, Inc.(NasdaqGS:MCRB) dropped from S&P Biotechnology Select Industry Index	Dec. 18	CI
Seres Therapeutics, Inc.(NasdaqGS:MCRB) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Huawei's new smart car firm valued up to $35 bln amid advanced stake talks -sources	Nov. 29	RE
Goldman Sachs Adjusts Price Target on Seres Therapeutics to $1.25 From $4, Maintains Sell Rating	Nov. 03	MT

Chart Seres Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of Clostridioides difficile infection (CDI) in patients 18 or older following antibacterial treatment for recurrent CDI. Building upon VOWST, it is developing novel microbiome therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, an oral microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to prevent enteric-derived infections and resulting blood stream infections and induce immune tolerance responses to reduce the incidence of GvHD in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Sector

Biotechnology & Medical Research

Calendar

2024-07-29 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Seres Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.9579 USD

Average target price

6.2 USD

Spread / Average Target

+547.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SERES THERAPEUTICS, INC.	-33.82%	145M
VERTEX PHARMACEUTICALS INCORPORATED	+7.60%	113B
REGENERON PHARMACEUTICALS, INC.	+10.39%	106B
ARGENX SE	+0.41%	22.27B
BIONTECH SE	-11.89%	22.22B
GENMAB A/S	-5.99%	19.43B
WUXI APPTEC CO., LTD.	-37.36%	17.87B
BEIGENE, LTD.	-5.25%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+6.57%	14.29B
SAREPTA THERAPEUTICS, INC.	+36.18%	12.52B

Bio Therapeutic Drugs